Treatments update
New treatments for lymphoma are being developed all the time. To be used in the UK, they have to be approved by an independent organisation who review clinical and cost effectiveness. This is called a Health Technology Assessment (HTA).
We are pleased that in the last few months, two new treatments have been approved by the National Institute for Health and Care Excellence (NICE) for use in England, Wales and Northern Ireland.
GlofitGemOx for people with relapsed or refractory diffuse large B-cell lymphoma
- What is it? GlofitGemOx, combines the targeted treatment glofitamab with the chemotherapy treatments gemcitabine and oxaliplatin. Glofitamab is a bispecific antibody.
- Who is it for? Adults with diffuse large B-cell lymphoma which has not responded to treatment (refractory) or has returned (relapsed), and who are not suitable for a stem cell transplant.
- Why has it been approved? People receiving this treatment in a trial called STARGLO had longer before their lymphoma returned, and lived longer overall, compared to the current treatment options.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (CLL)
- What is it? Venetoclax is a type of targeted treatment called a BCL-2 inhibitor.
- Who is it for? Adults with chronic lymphocytic leukaemia who have not received any treatment.
- Why has it been approved? Evidence has shown that this treatment works just as well as current options available and provides clinicians with another option for their patients.
Find out more about these two treatments and stay up-to-date on all future lymphoma HTA decisions in the news section of our website, filter by ‘New treatments and drug approvals’.
You can find out more about drug development, approval and funding, including how Lymphoma Action takes part in HTAs, at lymphoma-action.org.uk/DrugDevelopment
